275 related articles for article (PubMed ID: 35558005)
1. Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.
Zhai Y; Zhou X; Wang X
Ther Adv Med Oncol; 2022; 14():17588359221093745. PubMed ID: 35558005
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.
Mendez JS; Grommes C
Am Soc Clin Oncol Educ Book; 2018 May; 38():604-615. PubMed ID: 30231317
[TBL] [Abstract][Full Text] [Related]
3. [New treatment strategies for primary lymphoma of the central nervous system].
Seidel S; Kaulen L; von Baumgarten L
Nervenarzt; 2024 Feb; 95(2):117-124. PubMed ID: 37910181
[TBL] [Abstract][Full Text] [Related]
4. Primary central nervous system lymphoma.
Schaff LR; Grommes C
Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590
[TBL] [Abstract][Full Text] [Related]
5. Updates of primary central nervous system lymphoma.
Wu J; Zhou D; Zhu X; Zhang Y; Xiao Y
Ther Adv Hematol; 2024; 15():20406207241259010. PubMed ID: 38883164
[TBL] [Abstract][Full Text] [Related]
6. Recent advances and challenges in primary central nervous system lymphoma: a narrative review.
Ma L; Gong Q
Transl Cancer Res; 2023 May; 12(5):1335-1352. PubMed ID: 37304530
[TBL] [Abstract][Full Text] [Related]
7. Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.
Chihara D; Dunleavy K
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):73-79. PubMed ID: 33288483
[TBL] [Abstract][Full Text] [Related]
8. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review.
Guo HP; Dang XL; Kang L; Liu C; Liu XW
World Neurosurg; 2024 Apr; 188():161-169. PubMed ID: 38641241
[TBL] [Abstract][Full Text] [Related]
9. Update on Novel Therapeutics for Primary CNS Lymphoma.
Schaff LR; Grommes C
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771535
[TBL] [Abstract][Full Text] [Related]
10. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
11. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
Sasaki N; Nagane M
No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
[TBL] [Abstract][Full Text] [Related]
12. Advances in therapeutic strategies for primary CNS B-cell lymphomas.
Ramadan S; Radice T; Ismail A; Fiori S; Tarella C
Expert Rev Hematol; 2022 Apr; 15(4):295-304. PubMed ID: 35467473
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.
Nepal G; Khurana M; Bucheli DH; Bhandari S; Joshi U; Bhagat R; Rehrig JH; Pudasainee P; Shing YK; Ortiz JF; Ojha R; Gajurel BP; Quinonez J; Ruxmohan S; Albert T; Licata S; Stien J
Neurol Int; 2022 Jan; 14(1):99-108. PubMed ID: 35076567
[TBL] [Abstract][Full Text] [Related]
14. Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma.
Calimeri T; Steffanoni S; Foppoli M; Ponzoni M; Ferreri AJM
Expert Opin Ther Targets; 2021 Sep; 25(9):749-760. PubMed ID: 34606736
[No Abstract] [Full Text] [Related]
15. Advances and challenges in the treatment of primary central nervous system lymphoma.
Yang H; Xun Y; Yang A; Liu F; You H
J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
[TBL] [Abstract][Full Text] [Related]
16. Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?
Miyao K; Yokota H; Sakemura RL
Front Oncol; 2022; 12():1082235. PubMed ID: 36686821
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
[TBL] [Abstract][Full Text] [Related]
18. Targets and treatments in primary CNS lymphoma.
von Roemeling C; Ferreri AJM; Soussain C; Tun HW; Grommes C
Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38659230
[TBL] [Abstract][Full Text] [Related]
19. [New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review].
Hu BN; Yang X; Yuan YP; Chen YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):633-637. PubMed ID: 33812443
[TBL] [Abstract][Full Text] [Related]
20. Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report.
Zhou Y; Wang X; Lin X; Wang J; Yan X; Wen Y
AIDS Res Ther; 2023 Aug; 20(1):63. PubMed ID: 37644480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
